Dr. Chapman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
833 Chestnut St
Ste 1140
Philadelphia, PA 19107Phone+1 215-503-3744
Summary
- Dr. Andrew Chapman is the Director of the NCI designated Sidney Kimmel Cancer Center and a Medical Oncologist in Philadelphia, PA affiliated with Thomas Jefferson University Hospitals. He received his medical degree from Kansas City University College of Osteopathic Medicine and has been in practice 30 years. He specializes in Geriatric Oncology.
Education & Training
- Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 1991 - 1994
- University of Pennsylvania Health SystemResidency, Internal Medicine, 1988 - 1991
- Springfield HospitalInternship, Transitional Year, 1987 - 1988
- Kansas City University of Medicine and Biosciences College of Osteopathic MedicineClass of 1987
Certifications & Licensure
- PA State License 1988 - 2026
- DE State License 2017 - 2025
- NJ State License 2017 - 2025
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Philadelphia Top Doctor Castle Connelly, 2018-2023
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2013
- Join now to see all
Clinical Trials
- Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnos Start of enrollment: 2011 Jan 01
- Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2011 Apr 20
- Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide Start of enrollment: 2011 Nov 09
Publications & Presentations
PubMed
- 2 citationsFunctional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospe...Mina S Sedrak, Can-Lan Sun, Marie Bae, Rachel A Freedman, Allison Magnuson
Journal of Cancer Survivorship. 2024-08-01 - 1 citationsFalls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE...Jingran Ji, Marie Bae, Can-Lan Sun, Tanya M Wildes, Rachel A Freedman
Cancer. 2024-03-15 - 1 citationsProcess evaluation of a G8 screening tool implementation in an outpatient oncology center.Kristine Swartz, Andrew Chapman, Tingting Zhan, Kuang-Yi Wen
Journal of Geriatric Oncology. 2024-01-01
Press Mentions
- Party with a Purpose Supports Geriatric Oncology ResearchOctober 17th, 2024
- Jefferson Health’s Sidney Kimmel Cancer Center Names Vice President for Cancer DisparitiesMarch 18th, 2023
- Thomas Jefferson University Appoints Chair of Medical OncologyJanuary 22nd, 2023
- Join now to see all
Committees
- Member/Reviewer, ASCO Conquer Cancer Foundation Grant Selection Committee 2023 - Present
- Member, International Society of Geriatric Oncology Publication Committee 2021 - Present
- Member, International Society of Geriatric Oncology Designation Center Working Group 2021 - Present
Professional Memberships
- Member
- Member
- Member
- Member
- International Society of Geriatric Oncology (SIOG)Member
- Member
- Association of American Cancer InstitutesMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: